Resverlogix Corp. (TSX-V:RVX) wishes to stress the importance of a recent move by Pfizer Inc., the world’s largest pharmaceutical company, in announcing its intent to acquire Esperion Therapeutics, Inc. Resverlogix and Esperion are two of a limited number of companies that focus on the development of therapeutic approaches to raise the blood levels of high density lipoprotein (HDL), the so called ‘good cholesterol’. A recent clinical study published by the Journal of the American Medical Association demonstrated that increasing HDL produces significant regression of coronary atherosclerosis, the leading cause of cardiovascular disease. Pfizer will pay $1.3 billion USD or $35 per Esperion share.
